The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
about
Revisiting AMPA receptors as an antiepileptic drug targetMolecular targets for antiepileptic drug developmentPerampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptabilityIn the picture: disulfide-poor conopeptides, a class of pharmacologically interesting compoundsMechanisms of Action of Antiseizure Drugs and the Ketogenic DietEffects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: comparison with diazepam and interactions with flumazenilRemoving obstacles in neuroscience drug discovery: the future path for animal models.Inverse relationship between seizure expression and extrasynaptic NMDAR function following chronic NMDAR inhibition.Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.New anti-epileptic drugs.N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss.N-methyl-D-aspartate antagonists for stroke and head trauma.Basic mechanisms of psychotropic drugs.Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.Perampanel: What is its Place in the Management of Partial Onset Epilepsy?New developments in the treatment of partial-onset epilepsy.Synaptic and extrasynaptic plasticity in glutamatergic circuits involving dentate granule cells following chronic N-methyl-D-aspartate receptor inhibition.Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis.The effects of dietary choline.AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook.Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.Strategies for neuroprotection with glutamate antagonists. Extrapolating from evidence taken from the first stroke and head injury studies.Antiepileptic drug discovery: lessons from the past and future challenges.Developing drug strategies for the neuroprotective treatment of acute ischemic stroke.Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia.Identification and preclinical testing of novel antiepileptic compounds.Electrophysiological actions of felbamate on rat striatal neurones.Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs.Paradoxical proepileptic response to NMDA receptor blockade linked to cortical interneuron defect in stargazer micePlasticity of both excitatory and inhibitory synapses is associated with seizures induced by removal of chronic blockade of activity in cultured hippocampus.A Nonrewarding NMDA Receptor Antagonist Impairs the Acquisition, Consolidation, and Expression of Morphine Conditioned Place Preference in Mice.Competitive NMDA-receptor antagonists, LY 235959 and LY 233053, enhance the protective efficacy of various antiepileptic drugs against maximal electroshock-induced seizures in mice.Influence of D-cycloserine on the anticonvulsant activity of phenytoin and carbamazepine against electroconvulsions in mice.
P2860
Q24611163-5FE59AD6-EB9F-453A-8F8B-2FE4C1DB5F18Q24683346-20F94DFF-9331-4564-B30F-731A1B24A196Q26796447-03065E02-991E-4E1B-B69D-5DA3D1B57EC8Q28066688-9EC67324-2412-481E-8D4F-0B8ABDC16749Q28272457-8CE3F441-2F7E-4C38-BB68-32CD249BE009Q28368896-672E96C3-D8A2-48EA-9AF9-0596BBFE573BQ28755229-029D0088-AC4B-4D8F-A1BD-6BC3190969B9Q34015816-EC8E836A-AEF3-4B93-8B08-0C082321FD3AQ34075089-CE891D56-5A56-411C-891A-4142BA550246Q34119473-1D9200C8-15A4-40DF-BED3-97D6E47C49A7Q34409685-152E23E4-3417-46A5-ACFA-5F72343BBFD7Q34430163-098529DC-2523-4B59-8449-08F3725396E9Q34521815-2EA3F2F2-6A61-4B3E-9FDC-BD0D0DB36A82Q35040802-295CCBE7-EFE8-4A65-8061-0F445CE2C9DDQ35309243-53BEF9ED-7E87-4374-B06D-775F493ED8DBQ36337897-7FDD6962-6CB1-4FAE-BDFA-6C796FE0B9ADQ36700706-EEE40B1D-E6DF-427E-A632-AA06577BA127Q37430885-669D37DF-79F4-4ECD-A035-261FD1C5E639Q37936218-FDF6CB76-E00A-4AD7-9A05-C84CC48ABAEBQ38019570-58BD1881-3E58-41BE-B95C-336120E08885Q38537865-F0AD1150-0055-49E8-A161-9977173E9F6BQ38746272-41BB8113-086E-4E17-8A1F-7BC0AD079812Q40374513-66175FF7-AFD3-4416-97C7-3B2B0958AD6CQ40379424-08B80939-3892-480F-98F9-52B9723EF33DQ40429078-1E203518-F93F-423C-BD7D-70F46DE504D8Q40444545-FA9715A0-5582-4988-B79B-2CE67E7991C1Q40908835-8084BC8D-EAEB-4059-B2E9-9CD9D4974572Q42177610-B6384999-E420-41CC-B065-63373B18850EQ42277354-1773F537-C696-4B34-9559-35097C1F5DD4Q42631183-C029758A-62B8-4D7C-94D4-76A782CD6C17Q48491195-B79C08EC-789D-40BF-8C6E-9FF3BCAC1716Q50540419-1C599896-2FDE-4722-B55E-CC89F0B2EFE9Q52047509-D4C6E266-E1A2-4F90-B137-126E3545DA45Q52047511-E0D40CBA-4510-4413-9B7E-66D3089B8837
P2860
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
description
1993 nî lūn-bûn
@nan
1993 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@ast
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@en
The excitatory amino acid antagonist D-CPP-ene
@nl
type
label
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@ast
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@en
The excitatory amino acid antagonist D-CPP-ene
@nl
prefLabel
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@ast
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@en
The excitatory amino acid antagonist D-CPP-ene
@nl
P2093
P1433
P1476
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy.
@en
P2093
Patsalos PN
Sveinbjornsdottir S
Thompson PJ
P304
P356
10.1016/0920-1211(93)90031-2
P577
1993-10-01T00:00:00Z